Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

CVS-Aetna Deal Gets Nod -- WSJ

share with twitter share with LinkedIn share with facebook
share via e-mail
10/11/2018 | 02:48am EDT

By Anna Wilde Mathews and Micah Maidenberg

Justice Department antitrust enforcers cleared CVS Health Corp.'s acquisition of Aetna Inc. after the companies took steps to ease regulators' concerns, moving the nearly $70 billion deal a major step closer.

The Wall Street Journal had earlier reported that federal antitrust officials were preparing to give the deal a green light, but the overlap in the two companies' Medicare drug businesses had to be addressed. Aetna in late September announced the planned divestiture of its Medicare drug business to WellCare Health Plans Inc.

In announcing its approval, the Justice Department said that the WellCare deal "would fully resolve the Department's competition concerns."

The merger -- which brings together the giant drugstore chain and pharmacy-benefit manager with the No. 3 health insurer -- needs some state approvals to complete the deal.

State attorneys general from California, Florida, Hawaii, Mississippi and Washington joined the Justice Department in filing a civil suit Wednesday asking the U.S. District Court for the District of Columbia to require the sale to WellCare as a condition of the merger.

CVS said that it already had gotten "many" of the state approvals it needs. "We are pleased to have reached an agreement with the Justice Department that maintains the strategic benefits and value creation potential of our combination with Aetna," said CVS's chief executive, Larry Merlo. "We are now working to complete the remaining state reviews."

Aetna rival Cigna Corp. has already gotten Justice Department antitrust clearance for its acquisition of Express Scripts Holding Co., which also brings together a major health insurer with a pharmacy-benefit manager.

CVS and Aetna operate in largely different businesses, with their most direct overlap coming in selling plans under the Medicare prescription-drug program, known as Part D.

CVS has the largest market share in the Medicare drug-plan business, with around 6.1 million members, according to a recent tally from Wells Fargo. Aetna is the fifth-biggest Part D seller, with around 2.2 million members, according to Wells Fargo.

To preserve competition where CVS and Aetna sell Part D plans head-to-head, the Justice Department had been expected to require the companies to sell off parts of their Part D business to a competitor that would compete with the newly merged firm. WellCare already had around 1.1 million Part D enrollees.

Also on Wednesday, CVS said accounting chief and controller Eva Boratto would become the company's next finance chief. Shawn Guertin, who is now Aetna's CFO, had been expected to take over that role in the combined company. Mr. Guertin, who CVS said was leaving for personal and family reasons, will remain with the company until June 2019 to assist in the Aetna integration.

The company also said it would add three additional Aetna directors -- Edward Ludwig, Fernando Aguirre and Roger Farah -- to its board after the transaction closes. The latest move, including the previously announced plan to add current Aetna Chief Executive Mark Bertolini, would bring the number of people on CVS's board to 16.

Write to Anna Wilde Mathews at anna.mathews@wsj.com and Micah Maidenberg at micah.maidenberg@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
CVS HEALTH CORPORATION 0.53% 53.07 Delayed Quote.-19.43%
WELLCARE HEALTH PLANS 0.38% 275.53 Delayed Quote.16.27%
share with twitter share with LinkedIn share with facebook
share via e-mail
05/21CVS HEALTH : To Host 2019 Investor Day For The Investment Community
05/17CVS HEALTH CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
05/15NEWS HIGHLIGHTS : Top Company News of the Day
05/15CVS HEALTH : to Require Third-Party Testing of Vitamins, Supplements
05/15CVS PHARMACY : Launches 'Tested to Be Trusted' Program for Vitamins and Suppleme..
05/09CVS PHARMACY : Completes Rollout of Time Delay Safes in All of Its Minnesota Pha..
05/06PREMIER : to Exit Specialty Pharmacy Operations in Deal With CVS Unit
05/06EXCLUSIVE : Hedge funds target Centene, may oppose WellCare deal - sources
05/02CVS HEALTH : to Close 46 Pharmacy Locations - Update
05/02CVS HEALTH : to Close 46 Pharmacy Locations
More news
Financials ($)
Sales 2019 252 B
EBIT 2019 14 375 M
Net income 2019 6 545 M
Debt 2019 64 157 M
Yield 2019 3,76%
P/E ratio 2019 10,51
P/E ratio 2020 9,33
EV / Sales 2019 0,53x
EV / Sales 2020 0,49x
Capitalization 68 579 M
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 68,5 $
Spread / Average Target 30%
EPS Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
Eva C. Boratto Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors